New study "adds to the evidence of obesity-associated advantages," researchers conclude.
In a small study, intermittent vs continuous administration of IV iron resulted in less hemoglobin variability in hemodialysis patients with anemia.
Researchers found "no clinically meaningful differences" in efficacy and safety between the biosimilar epoetin alfa-epbx and epoetin alfa.
Patients with vs without anemia prior to starting hemodialysis (HD) were more likely to die despite achieving target hemoglobin levels at month 4 after HD initiation.
Anemia control may be one more reason to treat elevated parathyroid hormone levels.
Anemia is 66% and 84% more likely to develop among patients in the 3rd and 4th quartiles of serum fibroblast growth factor 23 level vs those in the 1st quartile.
Retacrit is biosimilar to the drugs Epogen and Procrit.
In a study, increases in red blood cell distribution width during the first year of dialysis was associated with greater risks for death.
Patients' mean hemoglobin levels stayed relatively stable after converting from an erythropoiesis-stimulating agent to the investigational drug.
New study shows that IV iron repletion with sodium ferric gluconate complex increased platelet count significantly at week 3 post-infusion and non-significantly at week 4.
Clinicians should advise women who could become pregnant to use effective contraception before and after taking the anemia drug.
In a study, use of anticoagulants was associated with 85% fewer atherosclerotic events.
In a trial, oral calcitriol of 0.5 mcg daily did not reduce hepcidin levels in patients with stage 3 to 4 CKD.
Dialysis patients receiving more or less than 200 mg per month of IV iron had similar risks of death, infection, cardiovascular disease, and hospitalization, meta-analysis shows.
The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.
In a 52-week trial, more than half of nondialysis-dependent chronic kidney disease patients with anemia treated with oral iron had no rise in their hemoglobin levels.
Patients with hemoglobin values of 9.7 g/dL or below had more than double the risk for hemorrhagic stroke compared with patients with hemoglobin values of 11.2 g/dL or above.
The safety profile of CERA is similar for children as for adults.
To support ESA therapy, IV iron at doses below 300 mg/month may be most effective for the average hemodialysis patient, according to an observational study.
Urinary ceruloplamin has potential to be a chronic kidney disease biomarker for patients with sickle cell anemia.
Researchers tested once weekly and biweekly administration of darbepoetin alfa in children aged 1 to 18 years not previously treated with an erythropoiesis-stimulating agent.
Researchers find no significant difference in the median erythropoietin resistance index between patients with versus without residual renal function.
To shed light on the often-challenging management of this common condition, a case of a hypothetical patient was presented to a doctor who specializes in advanced heart failure and transplant cardiology.
High doses of iron are associated with a significantly higher risk of cardiovascular disease, regardless of the dose of erythropoiesis-stimulating agent.
Study results show that the phosphate binder was superior to placebo in raising hemoglobin levels in non-dialysis-dependent CKD patients with iron-deficiency anemia.
Intravenous iron and erythropoietin produced a similar hemoglobin response among hemodialysis patients with moderate anemia.
The group targeting higher hemoglobin values experienced less decline in graft function.
HD patients with untreated or ineffectively treated anemia prior to dialysis initiation were more likely to die than those who had consistently well-treated anemia.
In a study, end-stage renal disease was 31% more likely to develop in CKD patients with versus without anemia.
CKD patients in the 3rd and 4th quartiles of c-terminal serum fibroblast growth factor 23 had a 74% and 73% higher risk for anemia compared with those in the 1st quartile.
Renal and Urology News Articles
- Acute Renal Failure in CKD Patients Less Likely With PCI
- Gout Associated With Increased Risk of Developing Erectile Dysfunction
- The Potential Role for PARP Inhibitors in Prostate Cancer
- More Targeted Sodium Reduction Strategies Proposed
- Cytoreductive Surgery for Metastatic PCa Linked to More Complications
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)